Inhaled IPF therapy moves to Phase 2 as early trial shows promise

The inhaled therapy MNKD-201 was tolerated well in people with idiopathic pulmonary fibrosis (IPF) in a Phase 1 clinical trial, and a Phase 2 study to further test it is underway, the treatment’s developer said. The Phase 2 trial, INFLO-2 (NCT07679893), aims to enroll more than 200 adults with IPF, ages 40 to 80, who […] The post Inhaled IPF therapy moves to Phase 2 as early trial shows promise…